Journal Citation Reports Science Citation Index
Total Page：16
File Type：pdf, Size：1020Kb
Load more
Recommended publications
-
Print Special Issue Flyer
IMPACT FACTOR 5.863 an Open Access Journal by MDPI The Future Direction of Radiopharmaceutical Development for Cancer Theranostics Guest Editor: Message from the Guest Editor Dr. Martina Benešová Dear Colleagues Research Group Molecular Biology of Systemic The journal Pharmaceuticals is planning to publish a Radiotherapy, Research Program Special Issue covering the topic “The Future Direction of Imaging and Radiooncology, German Cancer Research Center Radiopharmaceutical Development for Cancer (DKFZ), Im Neuenheimer Feld Theranostics”, and I am cordially inviting you to contribute 223, D-69120 Heidelberg, an article to this volume. Germany. [email protected] The purpose of this Special Issue is to host research and review papers on the development of novel radiopharmaceuticals and therapy strategies for cancer theranostics, which hold a great promise for improved Deadline for manuscript patients’ outcomes in the future. Areas of interest include, submissions: closed (31 January 2020) but are not limited to: Identification of new targets for cancer theranostics; Design of novel radiopharmaceuticals for cancer theranostics; Evaluation of non-standard radionuclides potentially suitable for cancer theranostics; Experimental targeted radionuclide therapy strategies; Prospective combination therapy with targeted radionuclide therapy involved. mdpi.com/si/28102 SpeciaIslsue IMPACT FACTOR 5.863 an Open Access Journal by MDPI Editor-in-Chief Message from the Editor-in-Chief Dr. Jean Jacques Vanden Because of your expertise in the field of drug sciences, I Eynde kindly invite you to consider publishing your current work, Formerly head of the Department in the form of a research article or a review, in the open of Organic Chemistry (FS), University of Mons-UMONS, 7000 access electronic journal Pharmaceuticals. -
Near-Infrared Light-Triggered Theranostics for Tumor-Specific Enhanced Multimodal Imaging and Photothermal Therapy
Journal name: International Journal of Nanomedicine Article Designation: Original Research Year: 2017 Volume: 12 International Journal of Nanomedicine Dovepress Running head verso: Wu et al Running head recto: Near-infrared light-triggered open access to scientific and medical research DOI: http://dx.doi.org/10.2147/IJN.S137835 Open Access Full Text Article ORIGINAL RESEARCH Near-infrared light-triggered theranostics for tumor-specific enhanced multimodal imaging and photothermal therapy Bo Wu1,* Abstract: The major challenge in current clinic contrast agents (CAs) and chemotherapy is Bing Wan2,* the poor tumor selectivity and response. Based on the self-quench property of IR820 at high Shu-Ting Lu1 concentrations, and different contrast effect ability of Gd-DOTA between inner and outer of Kai Deng3 liposome, we developed “bomb-like” light-triggered CAs (LTCAs) for enhanced CT/MRI/ Xiao-Qi Li1 FI multimodal imaging, which can improve the signal-to-noise ratio of tumor tissue spe- Bao-Lin Wu1 cifically. IR820, Iohexol and Gd-chelates were firstly encapsulated into the thermal-sensitive nanocarrier with a high concentration. This will result in protection and fluorescence quench- Yu-Shuang Li1 ing. Then, the release of CAs was triggered by near-infrared (NIR) light laser irradiation, Ru-Fang Liao1 which will lead to fluorescence and MRI activation and enable imaging of inflammation. In 3 Shi-Wen Huang vitro and in vivo experiments demonstrated that LTCAs with 808 nm laser irradiation have Hai-Bo Xu1,2 shorter T1 relaxation time in MRI and stronger intensity in FI compared to those without 1Department of Radiology, Zhongnan irradiation. Additionally, due to the high photothermal conversion efficiency of IR820, the Hospital of Wuhan University, injection of LTCAs was demonstrated to completely inhibit C6 tumor growth in nude mice 2Department of Radiology, Union Hospital of Tongji Medical College, up to 17 days after NIR laser irradiation. -
The First Brazilian Electronic Scientific Publication Turns 20 Years Old Benedito Barraviera
Barraviera Journal of Venomous Animals and Toxins including Tropical Diseases (2015) 21:52 DOI 10.1186/s40409-015-0050-7 EDITORIAL Open Access CEVAP Journal: the first Brazilian electronic scientific publication turns 20 years old Benedito Barraviera The year 2015 marks 350 years since the appearance of to the Vancouver Group, any electronic publication made the world’s first scientific publication and 20 years since available on the Internet constitutes a publication [7]. the publication of the Journal of Venomous Animals In 1995, there were about 100 electronic journals in and Toxins including Tropical Diseases (JVATiTD – the world, and the commercial Internet was starting in www.jvat.org) [1–3]. It was the first Brazilian electronic Brazil. In this context, the first Brazilian electronic scien- scientific publication – an official journal of the Center tific journal was launched in Botucatu, covering the area for the Study of Venoms and Venomous Animals of Toxinology. This new journal started one hundred (CEVAP) of São Paulo State University (UNESP) [4]. years after Vital Brazil lived in Botucatu. It is a homage The printing-press revolution, one of the most im- we paid to this brilliant Brazilian scientist [4]. The Journal portant breakthroughs for humanity, began about 1465 of Venomous Animals and Toxins (JVAT) circulated until when Johannes Gutenberg invented a moveable mech- 2002. Between 1995 and 1999, it was distributed on floppy anical type for printing. In 1665, the first scientific jour- disks, between 2000 and 2002 on CD-ROM, and only nals appeared in France and England, called respectively from 2003 on by the Internet, initially via the website the Journal des Sçavans and Philosophical Transactions. -
Bibliometric Analysis of Theranostics: Two Years in the Making Don N
Theranostics 2013, Vol. 3, Issue 7 527 Ivyspring International Publisher Theranostics 2013; 3(7):527-531. doi: 10.7150/thno.7021 Commentary Bibliometric Analysis of Theranostics: Two Years in the Making Don N. Ho1, Ki Young Choi1, Sung-Jong Lee1,2 1. Laboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, Maryland, USA 2. National Research Foundation of Korea, Daejeon, South Korea Corresponding author: [email protected] © Ivyspring International Publisher. This is an open-access article distributed under the terms of the Creative Commons License (http://creativecommons.org/ licenses/by-nc-nd/3.0/). Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited. Received: 2013.06.26; Accepted: 2013.07.02; Published: 2013.07.03 Abstract With the newly released impact factor from Thomson Reuters, we look at the first two years of the journal Theranostics under the scope of a new bibliometric designed for the analysis of emerging specialties and also for journals with a multidisciplinary approach. With this method, we are able to look at characteristics of an interdisciplinary field or a single journal subject area, and also, the bibliographic trends of their authors. We use this tool to examine authors from the journal Theranostics and compare them to similar au- thors in the field of theranostics, or theranosticians. Our document and co-citation analysis examines the growth and overlap of established knowledge networks with the incorporation of fields, topics, and disciplines; the quantification can also reflect the in- tellectual activity in combining leading edge developments in solidly grounded specialties. -
2021 ACS Publications Catalog
2021 CATALOG 1 ABOUT ACS AMERICAN CHEMICAL SOCIETY Table of Contents With more than 157,000 members, the American Chemical Society (ACS) is the world’s largest scientific society and one of the world’s leading sources of authoritative scientific information. A nonprofit organization chartered by Congress, ACS is at the forefront of the About ACS Publications .....................................................................................3 evolving worldwide chemical enterprise and the premier professional home for Editorial Excellence for 142 Years .................................................................................................................... 4 What Fuels ACS Publications’ Growth ........................................................................................................... 6 chemists, chemical engineers, and related professionals around the globe. ACS Publications’ Unsurpassed Performance ............................................................................................. 8 ACS Publications’ Impact on Chemistry.......................................................................................................10 Select Highlights from ACS Journals.............................................................................................................12 The ACS Publications Web Experience ........................................................................................................14 An Inspiring Online Platform ............................................................................................................................16 -
Microbubbles: from Cancer Detection to Theranostics
Cosgrove Cancer Imaging 2015, 15(Suppl 1):O17 http://www.cancerimagingjournal.com/content/15/S1/O17 ORALPRESENTATION Open Access Microbubbles: from cancer detection to theranostics David Cosgrove1,2 From International Cancer Imaging Society Meeting and 15th Annual Teaching Course (ICIS 2015) London, UK. 5-7 October 2015 Microbubbles have proven to be useful as diagnostic deployed: improve the specific binding or wait for clear- agents for ultrasound[1,2]. However, they have the ance of the unbound agent from the blood stream. potential for a far wider range of uses, both in unmodi- Another approach makes use of the fast time resolution of fied form (thus minimising regulatory barriers) and in ultrasound and tries to recognise which microbubbles are new forms[3]. These future uses may be divided into fixed and which are moving, thus enabling the bound diagnostic and therapeutic categories. population to be selectively imaged. Efforts have also been Routinediagnosticusesof microbubbles relevant to made to detect differences in the echoes from free versus oncology are mainly in the liver, where they have been bound microbubbles. endorsed by NICE for the characterisation of focal liver An important advance in allowing access to tissue lesions[4]. The key attribute here is the fact that malig- beyond the endothelium is the development of nanodro- nancies do not have the functioning sinusoidal system plets, made by cooling and pressurising microbubbles - at that accounts for the late retention of microbubbles in around 200nm in diameter, they are able to cross the the normal liver and in solid focal lesions - in this appli- endothelium, especially where its is leaky[7]. -
NANOMEDICINE: NANOTECHNOLOGY, BIOLOGY and MEDICINE Nanotechnology, Biology, and Medicine
NANOMEDICINE: NANOTECHNOLOGY, BIOLOGY AND MEDICINE Nanotechnology, Biology, and Medicine AUTHOR INFORMATION PACK TABLE OF CONTENTS XXX . • Description p.1 • Impact Factor p.1 • Abstracting and Indexing p.2 • Editorial Board p.2 • Guide for Authors p.4 ISSN: 1549-9634 DESCRIPTION . The mission of Nanomedicine: Nanotechnology, Biology, and Medicine (Nanomedicine: NBM) is to promote the emerging interdisciplinary field of nanomedicine. Nanomedicine: NBM is an international, peer-reviewed journal presenting novel, significant, and interdisciplinary theoretical and experimental results related to nanoscience and nanotechnology in the life and health sciences. Content includes basic, translational, and clinical research addressing diagnosis, treatment, monitoring, prediction, and prevention of diseases. Nanomedicine: NBM journal publishes articles on artificial cells, regenerative medicine, gene therapy, infectious disease, nanotechnology, nanobiotechnology, nanomedicine, stem cell and tissue engineering. Sub-categories include synthesis, bioavailability, and biodistribution of nanomedicines; delivery, pharmacodynamics, and pharmacokinetics of nanomedicines; imaging; diagnostics; improved therapeutics; innovative biomaterials; interactions of nanomaterials with cells, tissues, and living organisms; public health; toxicology; theranostics; point of care monitoring; nutrition; nanomedical devices; prosthetics; biomimetics; and bioinformatics. Article formats include Rapid Communications, Original Articles, Reviews, Perspectives, Technical and -
TOXICON an Interdisciplinary Journal on the Toxins Derived from Animals, Plants and Microorganisms
TOXICON An Interdisciplinary Journal on the Toxins Derived from Animals, Plants and Microorganisms AUTHOR INFORMATION PACK TABLE OF CONTENTS XXX . • Description p.1 • Audience p.2 • Impact Factor p.2 • Abstracting and Indexing p.2 • Editorial Board p.3 • Guide for Authors p.6 ISSN: 0041-0101 DESCRIPTION . Toxicon has an open access mirror Toxicon: X which has the same aims and scope, editorial board and peer-review process. To submit to Toxicon: X visit https://www.editorialmanager.com/TOXCX/default.aspx. An introductory offer Toxicon: X - full waiver of the Open Access fee. Toxicon's "aims and scope" are to publish: articles containing the results of original research on problems related to toxins derived from animals, plants and microorganisms papers on novel findings related to the chemical, pharmacological, toxicological, and immunological properties of natural toxinsmolecular biological studies of toxins and other genes from poisonous and venomous organisms that advance understanding of the role or function of toxins clinical observations on poisoning and envenoming where a new therapeutic principle has been proposed or a decidedly superior clinical result has been obtained. material on the use of toxins as tools in studying biological processes and material on subjects related to venom and antivenom problems. articles on the translational application of toxins, for example as drugs and insecticides epidemiological studies on envenoming or poisoning, so long as they highlight a previously unrecognised medical problem or provide insight into the prevention or medical treatment of envenoming or poisoning. Retrospective surveys of hospital records, especially those lacking species identification, will not be considered for publication. -
Complaint Alleges That OMICS Group, Inc., Along with Two Affiliated Companies
Case 2:16-cv-02022 Document 1 Filed 08/25/16 Page 1 of 54 1 DAVID C. SHONKA Acting General Counsel 2 IOANA RUSU GREGORY A. ASHE 3 Federal Trade Commission 4 600 Pennsylvania Avenue NW Washington, DC 20850 5 Telephone: 202-326-2077 (Rusu) Telephone: 202-326-3719 (Ashe) 6 Facsimile: 202-326-3768 7 Email: [email protected], [email protected] 8 DANIEL G. BOGDEN United States Attorney 9 BLAINE T. WELSH 10 Assistant United States Attorney Nevada Bar No. 4790 11 333 Las Vegas Blvd. South, Suite 5000 Las Vegas, Nevada 89101 12 Phone: (702) 388-6336 13 Facsimile: (702) 388-6787 14 Attorneys for Plaintiff 15 UNITED STATES DISTRICT COURT 16 DISTRICT OF NEVADA 17 FEDERAL TRADE COMMISSION, 18 Case No. 2:16-cv-02022 Plaintiff, 19 COMPLAINT FOR PERMANENT v. INJUNCTION AND OTHER 20 EQUITABLE RELIEF OMICS GROUP INC., a Nevada corporation, 21 also d/b/a OMICS Publishing Group, IMEDPUB 22 LLC, a Delaware corporation, CONFERENCE SERIES LLC, a Delaware corporation, and 23 SRINUBABU GEDELA, 24 Defendants. 25 26 Plaintiff, the Federal Trade Commission (“FTC”), for its Complaint alleges: 27 28 Page 1 of 16 Case 2:16-cv-02022 Document 1 Filed 08/25/16 Page 2 of 54 1 1. The FTC brings this action under Section 13(b) of the Federal Trade Commission Act 2 (“FTC Act”), 15 U.S.C. § 53(b) to obtain permanent injunctive relief, rescission or 3 reformation of contracts, restitution, the refund of monies paid, disgorgement of ill-gotten 4 monies, and other equitable relief for Defendants’ acts or practices in violation of 5 Section 5(a) of the FTC Act, 15 U.S.C. -
Evaluating Journal Impact Factor: a Systematic Survey of the Pros and Cons, and Overview of Alternative Measures
RESEARCH OPEN ACCESS ISSN 1678-9199 www.jvat.org Evaluating Journal Impact Factor: a systematic survey of the pros and cons, and overview of alternative measures Eugene Mech1,2, Muhammad Muneeb Ahmed2,3 , Edward Tamale2, Matthew Holek2, Guowei Li2,4, Lehana Thabane2,5,6,7,8,9,* 1 Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON, Canada. 2 Department of Health Research Methods, Evidence, and Impact (HEI), McMaster University, Hamilton, ON, Canada. 3 Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada. 4 Center for Clinical Epidemiology and Methodology (CCEM), Guangdong Second Provincial General Hospital, China. 5 Biostatistics Unit, Research Institute at St Joseph’s Healthcare, Hamilton, ON, Canada. 6 Department of Anesthesia, McMaster University, Hamilton, ON, Canada. 7 Department of Pediatrics, McMaster University, Hamilton, ON, Canada. 8 School of Nursing, McMaster University, Hamilton, ON, Canada. 9 School of Rehabilitation Science, McMaster University, Hamilton, ON, Canada. Keywords: Abstract Journal Impact Factor Background: Journal Impact Factor (JIF) has several intrinsic flaws, which highlight Bibliometrics its inability to adequately measure citation distributions or indicate journal quality. Alternative metrics Despite these flaws, JIF is still widely used within the academic community, resulting Citations and impact in the propagation of potentially misleading information. A critical review of the usefulness of JIF is needed including an overview of the literature to identify viable alternative metrics. The objectives of this study are: (1) to assess the usefulness of JIF by compiling and comparing its advantages and disadvantages; (2) to record the differential uses of JIF within research environments; and (3) to summarize and compare viable alternative measures to JIF. -
Current Trends in Cancer Nanotheranostics: Metallic, Polymeric, and Lipid-Based Systems
pharmaceutics Review Current Trends in Cancer Nanotheranostics: Metallic, Polymeric, and Lipid-Based Systems Catarina Oliveira Silva 1,† , Jacinta Oliveira Pinho 1,†, Joana Margarida Lopes 2, António J. Almeida 1, Maria Manuela Gaspar 1,* and Catarina Reis 1,3,* 1 iMedUlisboa, Faculty of Pharmacy, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal; [email protected] (C.O.S.); [email protected] (J.O.P.); [email protected] (A.J.A.) 2 Faculty of Pharmacy, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal; [email protected] 3 IBEB, Faculty of Sciences, Universidade de Lisboa, Campo Grande, 1749-016 Lisboa, Portugal * Correspondence: [email protected] (M.M.G.); [email protected] (C.R.); Tel.: +351-217-946-400 (ext. 14774 or 14244) (M.M.G. & C.R.); Fax: +351-217-946-470 (M.M.G. & C.R.) † Equal Contributors. Received: 2 December 2018; Accepted: 1 January 2019; Published: 8 January 2019 Abstract: Theranostics has emerged in recent years to provide an efficient and safer alternative in cancer management. This review presents an updated description of nanotheranostic formulations under development for skin cancer (including melanoma), head and neck, thyroid, breast, gynecologic, prostate, and colon cancers, brain-related cancer, and hepatocellular carcinoma. With this focus, we appraised the clinical advantages and drawbacks of metallic, polymeric, and lipid-based nanosystems, such as low invasiveness, low toxicity to the surrounding healthy tissues, high precision, deeper tissue penetration, and dosage adjustment in a real-time setting. Particularly recognizing the increased complexity and multimodality in this area, multifunctional hybrid nanoparticles, comprising different nanomaterials and functionalized with targeting moieties and/or anticancer drugs, present the best characteristics for theranostics. -
Theranostics Graphene and Other 2D Materials
Theranostics 2020, Vol. 10, Issue 12 5435 Ivyspring International Publisher Theranostics 2020; 10(12): 5435-5488. doi: 10.7150/thno.40068 Review Graphene and other 2D materials: a multidisciplinary analysis to uncover the hidden potential as cancer theranostics Laura Fusco1,2,3,#, Arianna Gazzi1,2,#, Guotao Peng4,#, Yuyoung Shin5, Sandra Vranic6, Davide Bedognetti3, Flavia Vitale7, Acelya Yilmazer8, Xinliang Feng9, Bengt Fadeel4,, Cinzia Casiraghi5,, Lucia Gemma Delogu2,9,10, 1. Department of Chemical and Pharmaceutical Sciences, University of Trieste, Trieste, Italy. 2. Fondazione Istituto di Ricerca Pediatrica, Città della Speranza, Padua, Italy. 3. Cancer Program, Sidra Medicine, Doha, Qatar. 4. Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden. 5. Department of Chemistry, University of Manchester, Manchester, UK. 6. Nanomedicine Lab, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK. 7. Department of Neurology, Bioengineering, Physical Medicine & Rehabilitation, Center for Neuroengineering and Therapeutics, University of Pennsylvania, Philadelphia, USA; Center for Neurotrauma, Neurodegeneration, and Restoration, Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, USA. 8. Stem Cell Institute, University of Ankara, Ankara, Turkey. 9. Department of Chemistry and Food Chemistry, School of Science, Technische Universität Dresden, Dresden, Germany. 10. Department of Biomedical Sciences, University of Padua, Padua, Italy. #These authors contributed equally